drugset / Trial / NCT07623135
Lumateperone for Late-Life Depression
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this research study is to examine how well a medication called lumateperone (Caplyta) works to relieve depression in older adults with treatment-resistant depression. Lumateperone (Caplyta) is approved by the U.S. Food and Drug Administration to treat Major Depressive Disorder in adults who are also taking another antidepressant medication. This study will compare lumateperone (Caplyta) to placebo (a sugar pill without medication).
Timeline
- Start
- 2026-06
- Primary completion
- 2028-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lumateperone | Small molecule | 10.5 mg | — |
| Subject | Lumateperone | Small molecule | 21 mg | — |
| Subject | Lumateperone | Small molecule | 42 mg | — |